A prospective validation study of sentinel lymph node biopsy in multicentric breast cancer: SMMaC trial
Background: Multicentric breast cancer is often considered a contra-indication for sentinel lymph node (SLN) biopsy due to concerns with sensitivity and false negative rate. To assess SLN feasibility and accuracy in multicentric breast cancer, the multi-institutional SMMaC trial was conducted. Methods: In this study 30 patients with multicentric breast cancer and a clinically negative axilla were prospectively included. Periareolar injection of radioisotope and blue dye was administered. In all patients SLN biopsy was validated by back-up completion axillary lymph node dissection. Results: the SLN was successfully identified in 30 of 30 patients (identification rate 100%). The incidence of axillary metastases was 66.7% (20/30). The false negative rate was 0% (0/20) and the sensitivity was 100% (20/20). The negative predictive value was 100% (10/10). Conclusion: SLN biopsy in multicentric breast cancer seems feasible and accurate and should therefore be considered in patients with multicentric breast cancer and clinically negative axilla.
|Axillary lymph node dissection, False negative rate, Multicentric breast cancer, Sentinel lymph node biopsy|
|European Journal of Surgical Oncology|
|Organisation||Department of Surgery|
van la Parra, R.F.D, de Roos, W.K, Contant, C.M.E, Bavelaar-Croon, C.D.L, Barneveld, P.C, & Bosscha, K. (2014). A prospective validation study of sentinel lymph node biopsy in multicentric breast cancer: SMMaC trial. European Journal of Surgical Oncology. doi:10.1016/j.ejso.2013.11.004